Susan Duty

Prof. Susan Duty


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
SDSusan Duty
Susan Duty
PJPeter Jenner
Peter Jenner

1 August 2002 in Current Drug Targets-CNS & Neurological Disorders
Verified
Journal Article
Closed access
PDF file
MOM. J. O'Neill
M. J. O'Neill
TMT. K. Murray
T. K. Murray
VLV. Lakics
V. Lakics
NVN. P. Visanji
N. P. Visanji
SDSusan Duty
Susan Duty
In the last five years there has been a rapid explosion of publications reporting that neuronal nicotinic acetylcholine receptors (nAChRs) play a role in neurodegenerative disorders. Furthermore, there is a well-established loss of nAChRs in post-mortem brains from patients with Alzheimers disease, Parkinsons disease and a range of other disorders. In the present review we discuss the evidence that nicotine and subtype selective nAChR ligands can provide neuroprotection in in vitro cell culture systems and in in vivo studies in animal models of such disorders. Whilst in vitro data pertaining to a protective effect of nicotine against nigral neurotoxins like MPTP is less robust, most studies agree that nicotine is protective against glutamate and β-amyloid toxicity in various culture systems. This effect appears to be mediated by α7 subtype nAChRs since the protection is blocked by α-bungarotoxin and is mimicked by α7 selective agonists. In vivo studies indicate that α7 receptors play a critical role in protection from cholinergic lesions and enhancing cognitive function. The exact subtype involved in the neuroprotectant effects seen in animal models of Parkinsons disease is not clear, but in general broad spectrum nAChR agonists appear to provide protection, while α4β2 receptors appear to mediate symptomatic improvements. Evidence favouring a protectant effect of nicotine against acute degenerative conditions is less strong, though some protection has been observed with nicotine pre-treatment in global ischaemia models. A variety of cellular mechanisms ranging from the production of growth factors through to inactivation of toxins and antioxidant actions of nicotine have been proposed to underlie the nAChR-mediated neuroprotection in vitro and in vivo. In summary, although the lack of subtype selective ligands has hampered progress, it is clear that in the future neuronal nAChR agonists could provide functional improvements and slow or halt the progress of several crippling degenerative diseases.

1 October 2003 in Experimental Neurology
Verified
Journal Article
Closed access
BHBrian Henry
Brian Henry
SDSusan Duty
Susan Duty
SFSusan H Fox
Susan H Fox
ACAlan R Crossman
Alan R Crossman
JBJonathan M Brotchie
Jonathan M Brotchie

1 January 2012 in Neurochemistry International
Verified
Journal Article
Closed access
MCMarica Carbone
Marica Carbone
SDSusan Duty
Susan Duty
MRMarcus Rattray
Marcus Rattray

6 January 2020 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
YBYazead Buhidma
Yazead Buhidma
KRKatarina Rukavina
Katarina Rukavina
KCKallol Ray Chaudhuri
Kallol Ray Chaudhuri
SDSusan Duty
Susan Duty
Pain is a commonly occurring non-motor symptom of Parkinson’s disease (PD). Treatment of pain in PD remains less than optimal and a better understanding of the underlying mechanisms would facilitate discovery of improved analgesics. Animal models of PD have already proven helpful for furthering the understanding and treatment of motor symptoms of PD, but could these models offer insight into pain in PD? This review addresses the current position regarding pain in preclinical models of PD, covering the face and predictive validity of existing models and their use so far in advancing understanding of the mechanisms contributing to pain in PD. While pain itself is not usually measured in animals, nociception in the form of thermal, mechanical or chemical nociceptive thresholds offers a useful readout, given reduced nociceptive thresholds are commonly seen in PD patients. Animal models of PD including the reserpine-treated rat and neurodegenerative models such as the MPTP-treated mouse and 6-hydroxydopamine (6-OHDA)-treated rat each exhibit reduced nociceptive thresholds, supporting face validity of these models. Furthermore, some interventions known clinically to relieve pain in PD, such as dopaminergic therapies and deep brain stimulation of the subthalamic nucleus, restore nociceptive thresholds in one or more models, supporting their predictive validity. Mechanistic insight gained already includes involvement of central and spinal dopamine and opioid systems. Moving forward, these preclinical models should advance understanding of the cellular and molecular mechanisms underlying pain in PD and provide test beds for examining the efficacy of novel analgesics to better treat this debilitating non-motor symptom.

1 August 2019 in Current Opinion in Neurology
Verified
Journal Article
Closed access
KRKatarina Rukavina
Katarina Rukavina
VLValentina Leta
Valentina Leta
CSCarolina Sportelli
Carolina Sportelli
YBYazead Buhidma
Yazead Buhidma
SDSusan Duty
Susan Duty
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
Purpose of review: In this review, we discuss the most recent evidence on mechanisms underlying pathological nociceptive processing in Parkinson's disease patients, as well as novel treatment strategies. Recent findings: In Parkinson's disease, specific neurodegenerative changes may cause alterations in nociceptive processing at multiple levels. Optimization of dopaminergic therapies should always be the first step in the management of Parkinson's disease pain. Reportedly, rotigotine transdermal patch, a monoamine oxidase type B inhibitor safinamide (as an add-on therapy to levodopa), subcutaneous apomorphine and intrajejunal levodopa infusion therapy may have a beneficial effect on pain sensations in Parkinson's disease patients. Among the nondopaminergic pharmacological therapies, prolonged-release oxycodone/naloxone and duloxetine may be effective in the treatment of chronic pain in Parkinson's disease. Botulinum toxin (BTX) injections should be considered for the treatment of dystonic Parkinson's disease pain. Deep brain stimulation (DBS) may lead to pain relief with a long-lasting effect in Parkinson's disease patients. Physiotherapy and physical activity in general are essential for Parkinson's disease patients suffering from pain. Summary: Pain in Parkinson's disease is not simply a consequence of motor complainants. The management of Parkinson's disease-related pain implicates maintenance of stable levels of dopaminergic drugs. Nondopaminergic pharmacological therapies (prolonged-release oxycodone/naloxone, duloxetine, BTX) and nonpharmacological interventions (DBS, physiotherapie) may also be beneficial in treatment of Parkinson's disease pain.